Colorectal cancer

David Cunningham, Wendy Atkin, Heinz Josef Lenz, Henry T. Lynch, Bruce Minsky, Bernard Nordlinger, Naureen Starling

Research output: Contribution to journalReview article

1040 Citations (Scopus)

Abstract

Substantial progress has been made in colorectal cancer in the past decade. Screening, used to identify individuals at an early stage, has improved outcome. There is greater understanding of the genetic basis of inherited colorectal cancer and identification of patients at risk. Optimisation of surgery for patients with localised disease has had a major effect on survival at 5 years and 10 years. For rectal cancer, identification of patients at greatest risk of local failure is important in the selection of patients for preoperative chemoradiation, a strategy proven to improve outcomes in these patients. Stringent postoperative follow-up helps the early identification of potentially radically treatable oligometastatic disease and improves long-term survival. Treatment with adjuvant fluoropyrimidine for colon and rectal cancers further improves survival, more so in stage III than in stage II disease, and oxaliplatin-based combination chemotherapy is now routinely used for stage III disease, although efficacy must be carefully balanced against toxicity. In stage II disease, molecular markers such as microsatellite instability might help select patients for treatment. The integration of targeted treatments with conventional cytotoxic drugs has expanded the treatment of metastatic disease resulting in incremental survival gains. However, biomarker development is essential to aid selection of patients likely to respond to therapy, thereby rationalising treatments and improving outcomes.

Original languageEnglish
Pages (from-to)1030-1047
Number of pages18
JournalThe Lancet
Volume375
Issue number9719
DOIs
StatePublished - 2010

Fingerprint

Colorectal Neoplasms
oxaliplatin
Survival
Rectal Neoplasms
Patient Selection
Therapeutics
Microsatellite Instability
Combination Drug Therapy
Colonic Neoplasms
Biomarkers
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Cunningham, D., Atkin, W., Lenz, H. J., Lynch, H. T., Minsky, B., Nordlinger, B., & Starling, N. (2010). Colorectal cancer. The Lancet, 375(9719), 1030-1047. https://doi.org/10.1016/S0140-6736(10)60353-4

Colorectal cancer. / Cunningham, David; Atkin, Wendy; Lenz, Heinz Josef; Lynch, Henry T.; Minsky, Bruce; Nordlinger, Bernard; Starling, Naureen.

In: The Lancet, Vol. 375, No. 9719, 2010, p. 1030-1047.

Research output: Contribution to journalReview article

Cunningham, D, Atkin, W, Lenz, HJ, Lynch, HT, Minsky, B, Nordlinger, B & Starling, N 2010, 'Colorectal cancer', The Lancet, vol. 375, no. 9719, pp. 1030-1047. https://doi.org/10.1016/S0140-6736(10)60353-4
Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B et al. Colorectal cancer. The Lancet. 2010;375(9719):1030-1047. https://doi.org/10.1016/S0140-6736(10)60353-4
Cunningham, David ; Atkin, Wendy ; Lenz, Heinz Josef ; Lynch, Henry T. ; Minsky, Bruce ; Nordlinger, Bernard ; Starling, Naureen. / Colorectal cancer. In: The Lancet. 2010 ; Vol. 375, No. 9719. pp. 1030-1047.
@article{7ee17beaf8c44e3cac556c3557d27646,
title = "Colorectal cancer",
abstract = "Substantial progress has been made in colorectal cancer in the past decade. Screening, used to identify individuals at an early stage, has improved outcome. There is greater understanding of the genetic basis of inherited colorectal cancer and identification of patients at risk. Optimisation of surgery for patients with localised disease has had a major effect on survival at 5 years and 10 years. For rectal cancer, identification of patients at greatest risk of local failure is important in the selection of patients for preoperative chemoradiation, a strategy proven to improve outcomes in these patients. Stringent postoperative follow-up helps the early identification of potentially radically treatable oligometastatic disease and improves long-term survival. Treatment with adjuvant fluoropyrimidine for colon and rectal cancers further improves survival, more so in stage III than in stage II disease, and oxaliplatin-based combination chemotherapy is now routinely used for stage III disease, although efficacy must be carefully balanced against toxicity. In stage II disease, molecular markers such as microsatellite instability might help select patients for treatment. The integration of targeted treatments with conventional cytotoxic drugs has expanded the treatment of metastatic disease resulting in incremental survival gains. However, biomarker development is essential to aid selection of patients likely to respond to therapy, thereby rationalising treatments and improving outcomes.",
author = "David Cunningham and Wendy Atkin and Lenz, {Heinz Josef} and Lynch, {Henry T.} and Bruce Minsky and Bernard Nordlinger and Naureen Starling",
year = "2010",
doi = "10.1016/S0140-6736(10)60353-4",
language = "English",
volume = "375",
pages = "1030--1047",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9719",

}

TY - JOUR

T1 - Colorectal cancer

AU - Cunningham, David

AU - Atkin, Wendy

AU - Lenz, Heinz Josef

AU - Lynch, Henry T.

AU - Minsky, Bruce

AU - Nordlinger, Bernard

AU - Starling, Naureen

PY - 2010

Y1 - 2010

N2 - Substantial progress has been made in colorectal cancer in the past decade. Screening, used to identify individuals at an early stage, has improved outcome. There is greater understanding of the genetic basis of inherited colorectal cancer and identification of patients at risk. Optimisation of surgery for patients with localised disease has had a major effect on survival at 5 years and 10 years. For rectal cancer, identification of patients at greatest risk of local failure is important in the selection of patients for preoperative chemoradiation, a strategy proven to improve outcomes in these patients. Stringent postoperative follow-up helps the early identification of potentially radically treatable oligometastatic disease and improves long-term survival. Treatment with adjuvant fluoropyrimidine for colon and rectal cancers further improves survival, more so in stage III than in stage II disease, and oxaliplatin-based combination chemotherapy is now routinely used for stage III disease, although efficacy must be carefully balanced against toxicity. In stage II disease, molecular markers such as microsatellite instability might help select patients for treatment. The integration of targeted treatments with conventional cytotoxic drugs has expanded the treatment of metastatic disease resulting in incremental survival gains. However, biomarker development is essential to aid selection of patients likely to respond to therapy, thereby rationalising treatments and improving outcomes.

AB - Substantial progress has been made in colorectal cancer in the past decade. Screening, used to identify individuals at an early stage, has improved outcome. There is greater understanding of the genetic basis of inherited colorectal cancer and identification of patients at risk. Optimisation of surgery for patients with localised disease has had a major effect on survival at 5 years and 10 years. For rectal cancer, identification of patients at greatest risk of local failure is important in the selection of patients for preoperative chemoradiation, a strategy proven to improve outcomes in these patients. Stringent postoperative follow-up helps the early identification of potentially radically treatable oligometastatic disease and improves long-term survival. Treatment with adjuvant fluoropyrimidine for colon and rectal cancers further improves survival, more so in stage III than in stage II disease, and oxaliplatin-based combination chemotherapy is now routinely used for stage III disease, although efficacy must be carefully balanced against toxicity. In stage II disease, molecular markers such as microsatellite instability might help select patients for treatment. The integration of targeted treatments with conventional cytotoxic drugs has expanded the treatment of metastatic disease resulting in incremental survival gains. However, biomarker development is essential to aid selection of patients likely to respond to therapy, thereby rationalising treatments and improving outcomes.

UR - http://www.scopus.com/inward/record.url?scp=77949437015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949437015&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(10)60353-4

DO - 10.1016/S0140-6736(10)60353-4

M3 - Review article

C2 - 20304247

AN - SCOPUS:77949437015

VL - 375

SP - 1030

EP - 1047

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9719

ER -